July 13, 2018
Takeda Pharmaceutical said on July 11 that single-agent Ninlaro (ixazomib) demonstrated a statistically significant extension in progression-free survival (PFS) versus placebo as a maintenance therapy in post-transplant multiple myeloma (MM) patients. In a PIII study dubbed, TOURMALINE-MM3, Ninlaro achieved the...read more